An intestinal farnesoid x receptor-ceramide signaling axis modulates hepatic gluconeogenesis in mice

Diabetes

Volumn 66, Issue 3, 2017, Pages 613-626

  Xie, Cen ^a   Jiang, Changtao ^b,c   Shi, Jingmin ^a   Gao, Xiaoxia ^a   Sun, Dongxue ^a   Sun, Lulu ^b,c   Wang, Ting ^b,c   Takahashi, Shogo ^a   Anitha, Mallappa ^d   Krausz, Kristopher W ^a   Patterson, Andrew D ^d   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; ACETYL COENZYME A; CAFFEIC ACID PHENETHYL ESTER; CERAMIDE; CITRATE SYNTHASE; FARNESOID X RECEPTOR; INSULIN; PYRUVATE CARBOXYLASE; AMIDASE; CAFFEIC ACID DERIVATIVE; CELL RECEPTOR; CHOLOYLGLYCINE HYDROLASE; FARNESOID X-ACTIVATED RECEPTOR; ISOXAZOLE DERIVATIVE; PHENETHYL ALCOHOL; TAUROCHOLIC ACID; TAUROMURICHOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET INDUCED OBESITY; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; GENE EXPRESSION; GLUCONEOGENESIS; ILEUM EPITHELIUM; IN VIVO STUDY; INTESTINE EPITHELIUM CELL; LIPID BLOOD LEVEL; LIPOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WEIGHT CHANGE; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; C57BL MOUSE; DRUG EFFECTS; ILEUM; INTESTINE; INTESTINE FLORA; LIPID DIET; LIVER; LIVER MITOCHONDRION; METABOLISM;

ACETYL COENZYME A; AMIDOHYDROLASES; ANIMALS; BODY WEIGHT; CAFFEIC ACIDS; CERAMIDES; DIET, HIGH-FAT; GASTROINTESTINAL MICROBIOME; GLUCONEOGENESIS; ILEUM; INSULIN; INTESTINES; ISOXAZOLES; LIVER; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA, LIVER; PHENYLETHYL ALCOHOL; PYRUVATE CARBOXYLASE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TAUROCHOLIC ACID;

EID: 85019639940     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-0663     Document Type: Article

References (39)

1. Sharabi K, Tavares CD, Rines AK, Puigserver P. Molecular pathophysiology of hepatic glucose production. Mol Aspects Med 2015;46:21-33
2. Kumashiro N, Beddow SA, Vatner DF, et al. Targeting pyruvate carboxylase reduces gluconeogenesis and adiposity and improves insulin resistance. Diabetes 2013;62:2183-2194
3. Pietrocola F, Galluzzi L, Bravo-San Pedro JM, Madeo F, Kroemer G. Acetyl coenzyme A: A central metabolite and second messenger. Cell Metab 2015;21:805-821
4. Perry RJ, Camporez JP, Kursawe R, et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell 2015; 160:745-758
5. de Aguiar Vallim TQ, Tarling EJ, Edwards PA. Pleiotropic roles of bile acids in metabolism. Cell Metab 2013;17:657-669
6. Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006;103:1006-1011
7. Sayin SI, Wahlström A, Felin J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013;17:225-235
8. Li F, Jiang C, Krausz KW, et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 2013;4:2384
9. Jiang C, Xie C, Li F, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 2015;125:386-402
10. Smith K, Zeng X, Lin J. Discovery of bile salt hydrolase inhibitors using an efficient high-Throughput screening system. PLoS One 2014;9:e85344
11. Kim I, Ahn SH, Inagaki T, et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res 2007; 48:2664-2672
12. Bezerra RM, Veiga LF, Caetano AC, et al. Caffeic acid phenethyl ester reduces the activation of the nuclear factor kB pathway by high-fat diet-induced obesity in mice. Metabolism 2012;61:1606-1614
13. Lee YS, Li P, Huh JY, et al. Inflammation is necessary for long-Term but not short-Term high-fat diet-induced insulin resistance. Diabetes 2011;60:2474-2483
14. Arruda AP, Pers BM, Parlakgöl G, Göney E, Inouye K, Hotamisligil GS. Chronic enrichment of hepatic endoplasmic reticulum-mitochondria contact leads to mitochondrial dysfunction in obesity. Nat Med 2014;20:1427-1435
15. Prawitt J, Caron S, Staels B. Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization. Trends Endocrinol Metab 2014;25:235-244
16. Jiang C, Xie C, Lv Y, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun 2015;6:10166
17. Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006;116:1102-1109
18. Cariou B, van Harmelen K, Duran-Sandoval D, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 2006;281:11039-11049
19. Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 2010;51:771-784
20. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013;145:574.e1-582.e1
21. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al.; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, non-Alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet 2015;385:956-965
22. Watanabe M, Horai Y, Houten SM, et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J Biol Chem 2011;286:26913-26920
23. Flynn CR, Albaugh VL, Cai S, et al. Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery. Nat Commun 2015;6:7715
24. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000;102:731-744
25. Trabelsi MS, Daoudi M, Prawitt J, et al. Farnesoid X receptor inhibits glucagonlike peptide-1 production by enteroendocrine L cells. Nat Commun 2015;6:7629
26. Bikman BT, Summers SA. Ceramides as modulators of cellular and wholebody metabolism. J Clin Invest 2011;121:4222-4230
27. Turpin SM, Nicholls HT, Willmes DM, et al. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab 2014;20:678-686
28. Raichur S, Wang ST, Chan PW, et al. CerS2 haploinsufficiency inhibits b-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. [published correction appears in Cell Metab 2014;20:919]. Cell Metab 2014;20:687-695
29. Xia JY, Holland WL, Kusminski CM, et al. Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis. Cell Metab 2015;22:266-278
30. Chavez JA, Summers SA. A ceramide-centric view of insulin resistance. Cell Metab 2012;15:585-594
31. Boslem E, Meikle PJ, Biden TJ. Roles of ceramide and sphingolipids in pancreatic b-cell function and dysfunction. Islets 2012;4:177-187
32. Contreras C, González-García I, Martínez-Sánchez N, et al. Central ceramideinduced hypothalamic lipotoxicity and ER stress regulate energy balance. Cell Reports 2014;9:366-377
33. Capel F, Demaison L, Maskouri F, et al. Calcium overload increases oxidative stress in old rat gastrocnemius muscle. J Physiol Pharmacol 2005;56:369-380
34. Zhang L, Xie C, Nichols RG, et al. Farnesoid X receptor signaling shapes the gut microbiota and controls hepatic lipid metabolism. mSystems 2016; 1:e00070-16
35. Tolba MF, Omar HA, Azab SS, Khalifa AE, Abdel-Naim AB, Abdel-Rahman SZ. Caffeic acid phenethyl ester: A review of its antioxidant activity, protective effects against ischemia-reperfusion injury and drug adverse reactions. Crit Rev Food Sci Nutr 2016;56:2183-2190
36. Murtaza G, Karim S, Akram MR, et al. Caffeic acid phenethyl ester and therapeutic potentials. Biomed Res Int 2014;2014:145342
37. Akyol S, Ugurcu V, Altuntas A, Hasgul R, Cakmak O, Akyol O. Caffeic acid phenethyl ester as a protective agent against nephrotoxicity and/or oxidative kidney damage: A detailed systematic review. Scientific World Journal 2014; 2014:561971
38. Gonzalez FJ, Jiang C, Patterson AD. An intestinal microbiota-farnesoid x receptor axis modulates metabolic disease. Gastroenterology 2016;151:845-859
39. Fang S, Suh JM, Reilly SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 2015;21: 159-165